|
HPV vaccine
|
|
| Vaccine description | |
| Target disease | human papillomavirus |
| Type | Protein subunit |
| Identifiers | |
| CAS number | ? |
| ATC code | J07 J07 |
| PubChem | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | injection |
Human papillomavirus (HPV) vaccine is a vaccine that prevents infection with certain species of human papillomavirus associated with the development of cervical cancer, genital warts,[1] and some less common cancers (e.g., anal,[2] vulvar,[3] vaginal,[3] penile[2]). Two HPV vaccines are currently on the market: Gardasil and Cervarix.[4] Both vaccines protect against two of the HPV types that can contribute to the development of cervical cancer, and some other genital cancers; Gardasil also protects against two of the HPV types that cause genital warts.[1]
Public health officials in Australia, Canada, Europe and United States recommend vaccination of young women against HPV to prevent cervical cancer and genital warts, and to reduce the number of painful and costly treatments for cervical dysplasia, which is caused by HPV.[5] Worldwide, HPV is the most common sexually transmitted infection in adults.[6] For example, more than 80% of American women will have contracted at least one strain of HPV by age fifty.[7][8][9][10][11]
Although most women infected with genital HPV will not have complications from the virus,[12] worldwide there are an estimated 470,000 new cases of cervical cancer that result in 233,000 deaths per year.[13] About eighty percent of deaths from cervical cancer occur in poor countries.[14] In the United States, most of the approximately 11,000 cervical cancers found annually[15] occur in women who have never had a Pap smear, or not had one in the previous five years.
Since the vaccine only covers some high-risk types of HPV, experts still recommend regular Pap smear screening even after vaccination.[16]
Gardasil has been shown to also be effective in males, though it has not yet been approved by the FDA to be marketed as such.[2]
Contents
|
Safety
Gardasil is a 3 dose (injection) vaccine. There have been 24 million doses distributed in the United States, and there have been 13,758 Vaccine Adverse Event Reporting System (VAERS) reports following the vaccination. Ninety-three percent were reports of events considered to be non-serious (e.g., fainting, pain and swelling at the injection site (arm), headache, nausea and fever), and 7% were considered to be serious (death, permanent disability, life-threatening illness and hospitalization). There is no proven causal link between the vaccine and serious adverse effects - all reports are related by time only. That is, they are only related because the effect happened some time after the vaccination.[17]
There have been 39 deaths among women who took the vaccine reported to the CDC. Six are currently under investigation, and seven are unconfirmed because of a lack of patient identification information. None of the other 26 confirmed deaths were linked to the vaccine. Guillain-Barré Syndrome (GBS), a rare disorder that causes muscle weakness, has been reported after vaccination with Gardasil. There is no evidence suggesting that Gardasil causes or raises the risk of GBS. Additionally, there have been rare reports of blood clots forming in the heart, lungs and legs. Most of those who suffered blood clots were already at risk from other factors, such as taking oral contraceptives.[17]
Based on all of the information they have today, CDC continues to recommend Gardasil vaccination for the prevention of 4 types of HPV.[17] Merck, the manufacturer of Gardasil, will continue to test women who have received the vaccine to determine the vaccine's efficacy over a lifetime.
Note: information is current as of May 1, 2009.
History
In work that was initiated in the mid 1980s, the vaccine was developed, in parallel, by researchers at Georgetown University Medical Center, the University of Rochester, the University of Queensland in Australia, and the U.S. National Cancer Institute.[18] In 2006, the U.S. Food and Drug Administration approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil. According to a Merck press release,[19] in the second quarter 2007, it had been approved in 80 countries, many under fast-track or expedited review. Early in 2007, GlaxoSmithKline filed for approval in the United States for a similar preventive HPV vaccine, known as Cervarix. In June 2007 this vaccine was licenced in Australia, and it was approved in the European Union in September 2007.[20]
Therapeutic HPV vaccines
In addition to preventive vaccines, such as Gardasil and Cervarix, laboratory research and several human clinical trials are focused on the development of therapeutic HPV vaccines. In general these vaccines focus on the main HPV oncogenes, E6 and E7. Since expression of E6 and E7 is required for promoting the growth of cervical cancer cells (and cells within warts), it is hoped that immune responses against the two oncogenes might eradicate established tumors.[21]
Prevalence of genital HPV
United States
According to the Centers for Disease Control and Prevention, by the age of 50 more than 80% of American women will have contracted at least one strain of genital HPV.[22] Both men and women can be carriers of HPV.[23] HPV is the most common sexually transmitted infection in the US.[22] A large percentage of the American population is infected with genital HPV[24] because HPV is highly communicable. As a result, American public health experts recommend widespread HPV vaccination.[25]
Only a small percentage of women with HPV develop cervical cancer.[26] Each year, between 250,000 and 1 million American women are diagnosed with cervical dysplasia, which is caused by HPV and is a potential precursor to cervical cancer.[27] About 11,000 American women are diagnosed with cervical cancer every year, and about 3,700 die per year of the disease.[15] Most cancers occur in those who have not had Pap smears within the previous five years.
There are 19 "high-risk" HPV types that can lead to the development of cervical cancer or other genital/anal cancers; some forms of HPV, particularly type 16, have been found to be associated with a form of throat cancer.[28] Studies have found that human papillomavirus (HPV) infection is responsible for virtually all cases of cervical cancer.[26][29]
Condoms protect against HPV, but do not completely prevent transmission.[30][31][32] College freshmen women who used condoms consistently had a 37.8% per patient-year incidence of genital HPV, compared to an incidence of 89.3% among those who did not.[30][31][32]
No data is kept by the U.S. government on genital wart infection rates,[33] however it is estimated that 20 million people are presently infected with genital warts, and there are six million new cases of genital warts every year in the United States.[34]
Worldwide
Worldwide, cervical cancer is the fifth most deadly cancer in women.[35] There are an estimated 470,000 new cases of cervical cancer, and 233,000 deaths per year.[13]
Vaccination and public health
According to the American National Cancer Institute, "Widespread vaccination has the potential to reduce cervical cancer deaths around the world by as much as two-thirds, if all women were to take the vaccine and if protection turns out to be long-term. In addition, the vaccines can reduce the need for medical care, biopsies, and invasive procedures associated with the follow-up from abnormal Pap tests, thus helping to reduce health care costs and anxieties related to abnormal Pap tests and follow-up procedures."[16]
Current preventive vaccines protect against the two HPV types (16 and 18) that cause about 70% of cervical cancers worldwide.[36] Because of the distribution of HPV types associated with cervical cancer, the vaccines are likely to be most effective in Asia, Europe, and North America.[36] Vaccines that protect against more of the types common in cancers would prevent more cancers, and be less subject to regional variation.[36]
Only 41% of women with cervical cancer in the developing world are able to access medical treatment for their illness.[37] Therefore, prevention of HPV by vaccination may be a more effective way of lowering the disease burden in developing countries than cervical screening.[citation needed] However, individuals in many resource-limited nations, Kenya for example, are unable to afford the vaccine.[38]
Vaccine target populations
Gardasil and Cervarix are preventative vaccines and do not have efficacy for treating active HPV infection. They are recommended for women who are 9 to 25 years old and have yet to contract HPV. However, since it is unlikely that a woman will have already contracted all four viruses, and because HPV is primarily sexually transmitted, the U.S. Centers for Disease Control and Prevention has recommended vaccination for women up to 26 years of age.
When Gardasil was first introduced, it was recommended as a prevention for cervical cancer for women that were 25 years old or younger. New evidence suggests that all Human Papillomavirus (HPV) vaccines are effective in preventing cervical cancer for women up to 45 years of age.[39]
In November 2007, Merck presented new data on Gardasil. In an investigational study, their HPV vaccine reduced incidence of HPV 6, 11, 16 and 18-related persistent infection and disease in women through age 45. The study evaluated women who had not contracted at least one of the HPV types targeted by the vaccine by the end of the three-dose vaccination series. Merck planned to submit this data before the end of 2007 to the U.S. Food and Drug Administration (FDA), and to seek an indication for Gardasil for women through age 45.[40]
Vaccination during pregnancy
In the Gardasil clinical trials, 1,115 pregnant women received the HPV vaccine. Overall, the proportions of pregnancies with an adverse outcome were comparable in subjects who received Gardasil and subjects who received placebo.[41] However, the clinical trials had a relatively small sample size. Currently the vaccine is not recommended for pregnant women.[1] The long-term effects of the vaccine on fertility are not known, but no effects are anticipated.
Vaccination of males
Gardasil can also be used in males to reduce their risk of genital warts and precancerous lesions caused by HPV.[2] The reduction in precancerous lesions is expected to reduce the rates of penile and anal cancers in men.[2] Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women.[42] From a public health point of view, vaccinating men as well as women might be useful if it decreased the virus pool within the population. Gardasil is in particular demand among gay men, who are at significantly increased risk for genital warts, penile cancer, and anal cancer.[43]
As with females, the vaccine must be administered before infection with the HPV types covered by the vaccine occurs. Vaccination before adolescence makes it more likely that the recipient has not been exposed to HPV.
In the UK, HPV vaccines are licensed for boys aged 9–15.[44] Merck, the maker of Gardasil, is expected to ask the FDA for permission to market the vaccine in the United States for boys and men ages 9–26.[2] The vaccine is already available in the United States and can be used off label for the vaccination of males.[2]
Mechanism of action
The latest generation of preventive HPV vaccines is based on hollow virus-like particles (VLPs) assembled from recombinant HPV coat proteins. The vaccines target the two most common high-risk HPVs, types 16 and 18. Together, these two HPV types currently cause about 70 percent of all cervical cancer.[36] Gardasil also targets HPV types 6 and 11, which together currently cause about 90 percent of all cases of genital warts.[26]
Gardasil and Cervarix are designed to elicit virus-neutralizing antibody responses that prevent initial infection with the HPV types represented in the vaccine. The vaccines have been shown to offer 100 percent protection against the development of cervical pre-cancers and genital warts caused by the HPV types in the vaccine, with few or no side effects. The protective effects of the vaccine are expected to last a minimum of 4.5 years after the initial vaccination.[45]
While the study period was not long enough for cervical cancer to develop, the prevention of these cervical precancerous lesions (or dysplasias) is believed highly likely to result in the prevention of those cancers.[46]
Although a 2006 study suggests that the vaccines may offer limited protection against a few HPV types that are closely related to HPVs 16 and 18, there are other high-risk HPV types are not affected by the vaccines.[45] Ongoing research is focused on the development of HPV vaccines that will offer protection against a broader range of HPV types.[47] There is also substantial research interest in the development of therapeutic vaccines, which seek to elicit immune responses against established HPV infections and HPV-induced cancers.
Vaccine implementation
In developed countries, the widespread use of cervical "Pap smear" screening programs has reduced the incidence of invasive cervical cancer by 50% or more. Current preventive vaccines reduce, but do not eliminate the chance of getting cervical cancer. Therefore, experts recommend that women combine the benefits of both programs by seeking regular Pap smear screening, even after vaccination.[48]
Australia
Commencing in 2007 The Australian federal government began funding a voluntary program to make the Gardasil vaccine available free of charge to women aged 12–26 for a period of two years, with an ongoing vaccination program for 12- and 13-year-olds as part of the pre-existing high school vaccination program.[49][50]
The Australian government and the PBS (Pharmaceutical Benefits Scheme) have approved the vaccine for use and in 2007 began a nationwide vaccination program free of charge to schoolgirls in years 7 to 12. These programs are run by local councils with funding and vaccine supplies from the government. The subsidization approval process, however, appears to have been heavily influenced by political interference from politicians of all political parties, and by the Prime Minister who publicly advised that it would be approved (before approval). In addition, women between 18 and 26 years of age at the time of the first dose may receive the vaccine for free upon request from their general practitioner. After June 2009, the program will be scaled down to 12- and 13-year-old girls only. Australia also approved Gardasil for boys 9–15 years old, but Australia is not providing government funding for vaccinating boys.[51][52]
Canada
Canada has approved use of Gardasil[53]. Initiating and funding free vaccination programs has been left to individual Province/Territory Governments. In the provinces of Ontario, Prince Edward Island, Newfoundland and Nova Scotia,[54] free vaccinations to protect women against HPV were slated to begin in September 2007 and will be offered to girls ages 11–14. Similar vaccination programs are being planned in British Columbia and Quebec.[55][56][57]
France
On July 17, 2007, France issued a directive[58] authorizing state-aided voluntary vaccination for girls aged 14–23 years who have not yet become sexually active, or have been sexually active for less than a year. The state refunds 65% of the cost, based on a program of 3 vaccinations at €135 (slightly less than $200) per shot, meaning that the patient covers €141.75 (slightly more than $200).
Germany and Italy
On March 26, 2007, early approval for Gardasil vaccinations was granted in both Germany and Italy.[59]
Greece
On February 12, 2007, Greece made HPV vaccination mandatory for girls entering gymnasion (7th grade). All vaccines including hepatitis B are mandatory and are supplied free to everyone in Greece, with parents being allowed to opt out of vaccinating their kids. Cervarix and Gardasil are supplied free to all girls and women between the ages of 12 and 26.[60][61]
Kenya
Both Cervarix and Gardasil are approved for use within Kenya by the Pharmacy and Poison's Board. However at a cost of 20,000 Kenyan shillings, which is more than the average annual income for a family, the director of health promotion in the Ministry of Health, Nicholas Muraguri, states that many Kenyans are unable to afford the vaccine.[38]
Romania
In Novermber 2008, Romanian authorities launched a campaign to vaccinate 110,000 girls aged 10 and 11. The Ministry of Health acquired 330,000 vaccine doses for $23 million euros. By an order of the Ministry, the girls' parents must approve or reject the vaccination in writing, and must "fully assume the consequences for their children" if they reject the vaccination.[62]
New Zealand
From September 2008, Gardasil will be available for New Zealand girls and young women born in 1990 and 1991 through primary care and from 2009, the HPV immunization program will be part of the regular immunization schedule for 12-year-old girls.[citation needed][63]
South Korea
On July 27, 2007, South Korean government approved Gardasil for use in girls and women aged 9 to 26 and boys aged 9 to 15.[64] Approval for use in boys was based on safety and immunogenicity but not efficacy.
Sweden
In Sweden, starting January 1, 2010, girls born in the year 1999 or later and in the ages 10 to 12 can receive a free HPV vaccine.[65]
United Kingdom
In the UK the vaccine is licensed for girls and boys aged 9 to 15 and for women aged 16 to 26.[44]
HPV vaccination will be introduced into the national immunisation programme in September 2008, for girls aged 12–13 across the UK. Then, starting in autumn 2009, a two-year catch up campaign will vaccinate all girls up to 18 years of age. This catch up campaign will offer to vaccinate:
- girls aged between 16 and 18 from autumn 2009, and
- girls aged between 15 and 17 from autumn 2010.
By the end of the catch up campaign, all girls under 18 will have been offered the HPV vaccine.
When the HPV vaccination programme begins in 2008, women over the age of 18 will not be vaccinated as it would not be cost effective in preventing cervical cancer. This is because as soon as a woman becomes sexually active, she is at risk of infection with the virus.
It will be many years before the vaccination programme has an effect upon cervical cancer incidence so women are advised to continue accepting their invitations for cervical screening.[66]
United States
As of late 2007[update], about one quarter of US females age 13–17 years had received at least one of the three HPV shots.[67]
Legislation
Opt-out policies
Almost all pieces of legislation currently pending in the states that would make the vaccine mandatory for school entrance have an "opt-out" policy.[68]
State-by-State
| Parts of this article (those related to state vaccination legislation) may no longer be up to date. Please update this article to reflect recent events or newly available information, and remove this template when finished. Please see the talk page for more information. Last update: This section needs to be updated as the NCSL Updated their website on November 4, 2008 |
Other states are also preparing bills to handle issuing the HPV Vaccine.[68]
| State | Proposal | Status | Opt Out Policy |
|---|---|---|---|
| Alaska | Voluntary vaccination program | Passed | N/A |
| California | Bill would have required girls entering the sixth grade to be vaccinated. | Withdrawn for further consideration. | Yes |
| Colorado | Bill would require 12-year-old girls to be vaccinated to attend school. | Pending | Yes |
| Connecticut | Bill would require girls receive a first dose of the vaccine before entering the sixth grade. Allows parents to opt their daughters out on medical or religious grounds. | Pending | Yes |
| District of Columbia | Bill would require girls to be vaccinated before they turn 13 to attend school. | Pending | Yes |
| Florida | Bill would have required 11- and 12-year-old girls to be vaccinated to attend school. | Died in committee | Yes |
| Georgia | Bill would require girls entering the sixth grade to be vaccinated unless parents can't afford the vaccine or object to it on medical or religious grounds. | Died in Committee | Yes |
| Illinois | Bill would require girls entering the sixth grade to be vaccinated. | Pending | Yes |
| Kansas | Bill would require girls entering the sixth grade to be vaccinated. Allows parents to opt their daughters out on medical or religious grounds. | Pending | Yes |
| Kentucky | Bill would require girls entering middle school to be vaccinated. | Passed House, to Senate | Yes |
| Maryland | Bill would have required girls entering the sixth grade to be vaccinated. | Withdrawn | Yes |
| Massachusetts | Bill would require girls entering the sixth grade to be vaccinated. Allows parents to opt their daughters out on religious grounds. | Pending | Yes |
| Michigan | Bill would require girls entering the sixth grade to be vaccinated. | Pending. | Yes |
| Missouri | Bill would require girls entering the sixth grade to be vaccinated. Allows parents to opt their daughters out on medical or religious grounds. | Pending | Yes |
| Minnesota | Bill would require 12-year-old girls to be vaccinated to attend school. | Pending | Yes |
| Mississippi | Bill would have required girls entering the sixth grade to be vaccinated. | Died. Sponsor planning to re-introduce it with an opt-out clause. | No |
| Nevada | Bill would require health insurance companies to cover the cost of the vaccine | Passed into law | N/A |
| New Hampshire | Voluntary program provides vaccine free of charge to girls between the ages of eleven and eighteen. | Passed and presently in effect. | Yes |
| New Jersey | Bill would require girls in grades seven through 12 to be vaccinated. Allows parents to opt their daughters out on medical or religious grounds. | Pending | Yes |
| New Mexico | Bill would require nine- to 14-year-old girls to be vaccinated to attend school. | Passed legislature. Vetoed by governor. | Yes |
| Ohio | Bill would require girls entering the sixth grade to be vaccinated. | Pending | Yes |
| Oklahoma | Bill would require girls entering the sixth grade to be vaccinated. | Pending | Yes |
| South Carolina | Bill would require girls entering the seventh grade or 11 years of age to be vaccinated. Allows parents to opt their daughters out on medical or religious grounds. | Pending | Yes |
| Texas | Governor issued executive order requiring that girls entering the sixth grade be vaccinated. | Texas legislature overrode executive order and barred mandatory vaccination until at least 2011. | Yes |
| Vermont | Bill would require girls entering the sixth grade to be vaccinated. Allows parents to opt their daughters out on medical, moral or religious grounds. | Pending | Yes |
| Virginia | Bill requires girls entering the sixth grade to be vaccinated. | Passed the legislature. Goes into effect Oct. 1, 2008; to be implemented in fall of 2009. | Yes |
| West Virginia | Bill would require girls entering the sixth grade to be vaccinated. Allows parents to opt their daughters out on medical grounds. | Died | Yes |
Source: National Conference of State Legislatures, state legislatures
Immigrants
All vaccines recommended by the U.S. government for its citizens are required for green card applicants. Therefore HPV vaccine is required for young women seeking to immigrate to the United States. This requirement has also stirred controversy because of the cost of the vaccine, and because all the other vaccines so required prevent diseases which are spread by respiratory route and considered highly contagious.[69]
Opposition in the United States
Health insurance companies
There has been significant opposition from health insurance companies to covering the cost of the vaccine ($360).[70][71][72]
Religious right and conservative groups
Several conservative groups in the U.S. have publicly opposed the concept of making HPV vaccination mandatory for pre-adolescent girls, asserting that making the vaccine mandatory is a violation of parental rights. They also say that it will lead to early sexual activity, giving a sense of immunity to sexually transmitted disease. Both the Family Research Council and the group Focus on the Family support widespread (universal) availability of HPV vaccines but oppose mandatory HPV vaccinations for entry to public school.[73][74][75][76]
Many organizations disagree with the argument that the vaccine increases sexual activity among teens. Dr. Christine Peterson, director of the University of Virginia's Gynecology Clinic, said "The presence of seat belts in cars doesn't cause people to drive less safely. The presence of a vaccine in a person's body doesn't cause them to engage in risk-taking behavior they would not otherwise engage in." [77]
References
- ^ a b c CDC (2006). "STD Facts - HPV Vaccine". http://www.cdc.gov/std/HPV/STDFact-HPV-vaccine.htm. Retrieved on 2007-08-22.
- ^ a b c d e f g Cortez, Michelle Fay and Pettypiece, Shannon. "Merck Cancer Shot Cuts Genital Warts, Lesions in Men". Bloomberg News. (Bloomberg.com) 13 Nov 2008.
- ^ a b "FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers". 2008-09-12. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01885.html. Retrieved on 2008-10-12.
- ^ Glaxo cervical cancer shot approved in Australia Reuters (2007-05-21) Retrieved on 2007-05-25
- ^ Jacobs Institute for Women's Health New Report Examines Laws that Would Mandate HPV Vaccine for Young Women
- ^ Human Papilloma Virus – Common but with dire potential consequences
- ^ Planned Parenthood "In fact, the lifetime risk for contracting HPV is at least 50 percent for all sexually active women and men, and, it is estimated that, by the age of 50, at least 80 percent of women will have acquired sexually transmitted HPV (CDC, 2004; CDC, 2006)."
- ^ Medical News Today
- ^ Dunne EF, Unger ER, Sternberg M, et al. (February 2007). "Prevalence of HPV infection among females in the United States". JAMA: the journal of the American Medical Association 297 (8): 813–19. doi:. PMID 17327523.
- ^ American Social Health Association "Genital HPV is the most common STD in America; an estimated 80% of sexually active individuals will contract it at some point in their lives."
- ^ "Study Reveals High Infection Rate In Teens For Virus Linked To Cervical Cancer" Science Daily "The research, reported by Darron R. Brown, M.D., and colleagues at the Indiana University School of Medicine, found four out of five sexually active adolescent females infected with the human papillomavirus."
- ^ Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006). "HPV-mediated cervical carcinogenesis: Concepts and clinical implications". J. Pathol. 208 (2): 152–64. doi:. PMID 16362994. "cervical cancer is a rare complication of an hrHPV infection since most such infections are transient, not even giving rise to cervical lesions.".
- ^ a b "Information from FDA and CDC on Gardasil and its Safety". July 22, 2008. http://www.cdc.gov/vaccinesafety/vaers/FDA_and_CDC_Statement.htm. Retrieved on 2008-08-22.
- ^ Cervical Cancer Action - Funded by the Rockefeller Foundation
- ^ a b National Cancer Institute SEER fact sheet on cervical cancer accessed 30 Mar 2007.
- ^ a b "Human Papillomavirus (HPV) Vaccines: Q & A - National Cancer Institute". http://www.cancer.gov/cancertopics/factsheet/risk/HPV-vaccine. Retrieved on 2008-07-18.
- ^ a b c "CDC VAERS - Vaccine Adverse Event Reporting System". http://www.cdc.gov/vaccinesafety/vaers/gardasil.htm. Retrieved on 2009-04-30.
- ^ McNeil C (April 2006). "Who invented the VLP cervical cancer vaccines?". Journal of the National Cancer Institute 98 (7): 433. doi:. PMID 16595773.
- ^ Merck News Item
- ^ "Glaxo prepares to launch Cervarix after EU okay". http://www.reuters.com/article/governmentFilingsNews/idUSL2446805720070924. Retrieved on 2008-07-18.
- ^ Roden RB, Ling M, Wu TC (August 2004). "Vaccination to prevent and treat cervical cancer". Human pathology 35 (8): 971–82. doi:. PMID 15297964.
- ^ a b "HPV Vaccine - Questions & Answers for the Public". http://www.cdc.gov/vaccines/vpd-vac/hpv/hpv-vacsafe-effic.htm. Retrieved on 2008-08-22.
- ^ National Cancer Institute SEER fact sheet on cervical cancer accessed 30 Mar 2007.
- ^ "More American Girls And Women Have HPV Than First Thought". http://www.medicalnewstoday.com/articles/64137.php. Retrieved on 2008-05-28.
- ^ New Report Examines Laws that Would Mandate HPV Vaccine for Young Women George Washington University, December 27, 2007
- ^ a b c Lowy DR, Schiller JT (May 2006). "Prophylactic human papillomavirus vaccines". The Journal of clinical investigation 116 (5): 1167–73. doi:. PMID 16670757.
- ^ Women's Health Channel "Cervical Dysplasia: Overview, Risk Factors"]
- ^ D'Souza G, Kreimer AR, Viscidi R, et al. (May 2007). "Case-control study of human papillomavirus and oropharyngeal cancer". The New England journal of medicine 356 (19): 1944–56. doi:. PMID 17494927.
- ^ [1]
- ^ a b Cottler L, Garvin EC, Callahan C (September 2006). "Condom use and the risk of HPV infection". The New England journal of medicine 355 (13): 1388–9; author reply 1389. doi:. PMID 17014039.
- ^ a b Winer RL, Hughes JP, Feng Q, et al. (June 2006). "Condom use and the risk of genital human papillomavirus infection in young women". The New England journal of medicine 354 (25): 2645–54. doi:. PMID 16790697.
- ^ a b Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR (October 2004). "Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic". Sexually transmitted diseases 31 (10): 601–7. doi:. PMID 15388997. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0148-5717&volume=31&issue=10&spage=601.
- ^ Avert.org
- ^ Genital HPV Infection - CDC Fact Sheet
- ^ World Health Organization (February 2006). "Fact sheet No. 297: Cancer". http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Retrieved on 2007-12-01.
- ^ a b c d Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004-08-20). "Against which human papillomavirus types shall we vaccinate and screen? The international perspective.". Int J Cancer 111 (2): 278–85. doi:. PMID 15197783.
- ^ Wittet S. & Tsu V. (2008) Cervical cancer prevention and the Millenium Development Goals. Bulletin of the World Health Organization, 86, 488-490.
- ^ a b Cervarix Marketing in Kenya
- ^ "HPV Vaccine Update". Your Cancer Today. 2007-12-11. http://www.yourcancertoday.com/news/HPV-update.html.
- ^ 05 Nov 2007, New Data Presented on GARDASIL, Merck's Cervical Cancer Vaccine, in Women Through Age 45. Retrieved through web archive on February 23, 2009
- ^ Merck Pregnancy Registries - GARDASIL
- ^ Rosenthal, Elisabeth (2008-08-19). "Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise". The New York Times. http://www.nytimes.com/2008/08/20/health/policy/20vaccine.html?_r=1&hp=&adxnnl=1&oref=slogin&adxnnlx=1219244494-RoSoOUDyGcwdbs6sjLcrEw. Retrieved on 2008-08-20. "Said Dr. Raffle, the British cervical cancer specialist: “Oh, dear. If we give it to boys, then all pretense of scientific worth and cost analysis goes out the window.”"
- ^ Cancer Research UK. "Gay men seeking HPV vaccine". (http://info.cancerresearch.org). 23 Feb 2007.
- ^ a b "Gay men seek 'female cancer' jab". BBC. 2007-02-23. http://news.bbc.co.uk/1/hi/health/6342105.stm.
- ^ a b Harper DM, Franco EL, Wheeler CM, et al. (April 2006). "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial". Lancet 367 (9518): 1247–55. doi:. PMID 16631880.
- ^ "FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus". FDA. 2006-06-08. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html. Retrieved on 2007-02-04.
- ^ "New HPV Vaccine Under Study.". Medical College of Georgia, ScienceDaily. 2007-11-20. http://www.sciencedaily.com/releases/2007/11/071119113902.htm. Retrieved on 2008-03-01.
- ^ Cutts FT, Franceschi S, Goldie S et al. (2007). "Human papillomavirus and HPV vaccines: a review". Bull World Health Organ 85 (9): 719–26. doi:. PMID 18026629. http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862007000900018&lng=en&nrm=iso.
- ^ Australian Government To Fund Cervical Cancer Vaccine Gardasil
- ^ "Australian Government Funding Of Gardasil". Australian Government Department of Health and Ageing. 2006-11-28. http://www.health.gov.au/internet/main/publishing.nsf/Content/gardasil_hpv.htm. Retrieved on 2008-08-29.
- ^ Poljak, Vesna; Daley, Gemma (2006-11-29). "Australia to Subsidize Merck Cervical Cancer Vaccine (Update3)". Bloomberg. http://www.bloomberg.com/apps/news?pid=20601081&sid=adOT2d961UKo&refer=australia. Retrieved on 2007-01-26.
- ^ The Department of Health and Ageing (2007-08-13). "The National HPV Vaccination Program - Frequently Asked Questions for Young Women". http://www.health.gov.au/internet/standby/publishing.nsf/Content/young-women-faq. Retrieved on 2007-09-28.
- ^ Human Papillomavirus (HPV) Prevention and HPV Vaccine: Questions and Answers
- ^ HPV Immunization Launched
- ^ "McGuinty Government Launches Life-Saving HPV Immunization Program:". Premier of Ontario. 2007-08-02. http://www.premier.gov.on.ca/news/Product.asp?ProductID=1552&Lang=EN. Retrieved on 2007-12-02.
- ^ "HPV Immunization Launched". Province of Nova Scotia. 2007-06-20. http://www.gov.ns.ca/news/details.asp?id=20070620002. Retrieved on 2007-12-02.
- ^ "British Columbia To Launch Program To Provide HPV Vaccine to Sixth-Grade Girls Next Fall if Approved, Official Says". Kaiser Daily Women's Health Policy (Kaiser Family Foundation). 2007-08-09. http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=46766. Retrieved on 2007-12-02.
- ^ "Gardasil authorised for subsidised vaccination". French govt news release (in French). 2007-12-31. http://www.service-public.fr/actualites/00589.html. Retrieved on 2007-12-31.
- ^ Fagbire, OJ (2007-03-26). "Gardasil, Merck HPV Vaccine, Gets German And Italian Approval For Girls". Vaccine Rx. http://www.vaccinerx.com/news/cervical-cancer/gardasil-merck-hpv-vaccine-gets-german-and-italian-approval-for-girls-20070326-149-26.html. Retrieved on 2007-03-27.
- ^ fskilkis.gr - Tο εμβόλιο κατά του καρκίνου τραχήλου της μήτρας και Cervarix vs Gardasil , Φαρμακευτικός Σύλλογος Κιλκίς (Pharmacy Association of Kilkis).
- ^ iatronet.gr - Υγεία / Γυναικολογία - Μαιευτική / Καρκίνος του τραχήλου της μήτρας / Ο εμβολιασμός κατά του HPV στην Ελλάδα
- ^ (Romanian) Claudia, Marcu (21 November, 2008) "100.000 de fetiţe, injectate cu un vaccin controversat" (100,000 girls injected with a controversial vaccine) Gândul
- ^ http://www.cervicalcancervaccine.govt.nz/questions_and_answers.php#info_girls
- ^ "가다실 제품 허가 공지". 2007-06-27. http://www.msd-korea.com/content/corporate/news/announcement/company22-gardasil.html. Retrieved on 2007-08-06.
- ^ "Information om det allmänna barnvaccinationsprogrammet" (in Swedish). Smittskyddsinstitutet. http://www.smittskyddsinstitutet.se/hem/mest-efterfragat/allmanna-vaccinationsprogrammet/. Retrieved on 2009-05-06. "Den 1 januari 2010 införs vaccin mot Humant papillomvirus (HPV) i programmet för flickor, födda 1999 eller senare, som skydd mot livmoderhalscancer orsakad av HPV."
- ^ "NHS Cervical Screening Program". http://www.cancerscreening.nhs.uk/cervical/index.html. Retrieved on 2008-06-26.
- ^ "1 in 4 US teen girls got cervical cancer shot". http://www.washingtonpost.com/wp-dyn/content/article/2008/10/09/AR2008100901452.html?sub=new. Retrieved on 2008-10-12.
- ^ a b HPV Vaccine
- ^ MIRIAM JORDAN. "Gardasil Requirement for Immigrants Stirs Backlash". The Wall Street Journal. http://online.wsj.com/article/SB122282354408892791.html?. Retrieved on 2009-01-15.
- ^ HPV Vaccine - Why Your Doctor Doesn't Offer the HPV Vaccine - Gardasil
- ^ Public Health & Education Detroit News Examines Cost of HPV Vaccine Gardasil - Kaisernetwork.org
- ^ A question of protection
- ^ Sprigg, Peter (2006-07-15). "Pro-Family, Pro-Vaccine — But Keep It Voluntary". The Washington Post. http://www.washingtonpost.com/wp-dyn/content/article/2006/07/14/AR2006071401532.html. Retrieved on 2007-02-04.
- ^ Coyne, Brendan (2005-11-02). "Cervical Cancer Vaccine Raises 'Promiscuity' Controversy". The New Standard. http://newstandardnews.net/content/index.cfm/items/2552. Retrieved on 2006-08-28.
- ^ Family Research Council: Thursday, February 7, 2008 "IF07B01"
- ^ Focus on the Family Position Statement: Human Papillomavirus Vaccines
- ^ "Lifesaving Politics." Ms. Magazine. pp 12–13. Spring 2007.
External links
Information about the HPV and vaccination
- The HPV Vaccine Controversy Book: Sex, Cancer God and Politics-http://www.greenwood.com/catalog/C35011.aspx
- HPV, Cervical Cancer, and the New Vaccine, kaiserEDU.org Background Brief and Issue Module
- UCSB SexInfo's HPV Information Page
- News and commentary on HPV vaccines from the University of Pennsylvania Center for Bioethics
- The HPV research foundation
- Information about HPV and the HPV vaccine for teens from the Aware Foundation
- HPV and cervical cancer from the UK's leading cervical cancer charity Jo's Trust
- Australian Cervical Cancer Foundation - Free HPV vaccine to developing countries such as Nepal
- MedlinePlus on HPV (nih.gov)
- CDC STD Human Papillomavirus (HPV) Infection (cdc.gov)
Major media coverage
- Defusing the War Over the "Promiscuity" Vaccine, TIME Magazine, June 21, 2006
- Washington Post article about people's decision to get vaccine or not
Organizations in favor of vaccination
- Panel Unanimously Recommends Cervical Cancer Vaccine for Girls 11 and Up — The New York Times'
- What Is HPV - Background Information and Activist Tool Kit
Organizations opposed to vaccination
- HPV, Vaccines, and Gender Policy Considerations by Abby Lippman, Carolyn Shimmin, Ryan Melynk, Madeline Boscoe for the Canadian Women's Health Network. 2007.
- Vaccination Bill Mutates by Sigrid Fry-Revere
| The examples and perspective in this article may not represent a worldwide view of the subject. Please improve this article or discuss the issue on the talk page. |
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)


